Titan Pharmaceuticals Inc. (NASDAQ: TTNP) is 5.78% higher on its value in year-to-date trading and has touched a low of $2.82 and a high of $16.35 in the current 52-week trading range. The TTNP stock was last observed hovering at around $3.24 in the last trading session, with the day’s gains setting it 0.24% off its average median price target of $24.00 for the next 12 months. It is also 85.5% off the consensus price target high of $24.00 offered by 1 analysts, but current levels are 85.5% higher than the price target low of $24.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $3.48, the stock is 7.03% and -6.31% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.4 million and changing 7.41% at the moment leaves the stock -47.90% off its SMA200. TTNP registered -57.04% loss for a year compared to 6-month loss of -59.60%. The firm has a 50-day simple moving average (SMA 50) of $12.55% and a 200-day simple moving average (SMA200) of $341.93k.
The stock witnessed a 2.05% gain in the last 1 month and extending the period to 3 months gives it a -25.83%, and is 7.74% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.72% over the week and 5.91% over the month.
Titan Pharmaceuticals Inc. (TTNP) has around 21 employees, a market worth around $22.76M and $5.00M in sales. Distance from 52-week low is 23.40% and -78.72% from its 52-week high. The company has generated returns on investments over the last 12 months (-307.70%).
Titan Pharmaceuticals Inc. (TTNP) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Titan Pharmaceuticals Inc. (TTNP) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 3.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Titan Pharmaceuticals Inc. is expected to release its quarterly report on 05/20/2021 and quarterly earnings per share for the current quarter are estimated at -$0.9 with sales reaching $600k over the same period.The EPS is expected to grow by 7.90% this year, but quarterly earnings will post 1.40% year-over-year. Quarterly sales are estimated to shrink -50.70% in year-over-year returns.
Titan Pharmaceuticals Inc. (TTNP) Top Institutional Holders
23 institutions hold shares in Titan Pharmaceuticals Inc. (TTNP), with 333.32k shares held by insiders accounting for 5.08% while institutional investors hold 3.72% of the company’s shares. The shares outstanding are 6.65M, and float is at 6.55M with Short Float at 12.74%. Institutions hold 3.53% of the Float.
The top institutional shareholder in the company is Sabby Management, LLC with over 0.16 million shares valued at $0.8 million. The investor’s holdings represent 2.47% of the TTNP Shares outstanding. As of Sep 29, 2020, the second largest holder is Vanguard Group, Inc. (The) with 38363.0 shares valued at $0.19 million to account for 0.58% of the shares outstanding. The other top investors are Geode Capital Management, LLC which holds 17205.0 shares representing 0.26% and valued at over $85371.0, while Northern Trust Corporation holds 0.10% of the shares totaling 6424.0 with a market value of $31875.0.
Titan Pharmaceuticals Inc. (TTNP) Insider Activity
A total of 0 insider transactions have happened at Titan Pharmaceuticals Inc. (TTNP) in the last six months, with sales accounting for 0 and purchases happening 0 times.